NCT03704376

Brief Summary

This study will examine the potential differences between femoral nerve blockade (FNB) and adductor canal blockade (ACB) for pain control and quadriceps muscle activation for patients following anterior cruciate ligament (ACL) reconstruction.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
125

participants targeted

Target at P50-P75 for phase_4

Timeline
Completed

Started Feb 2016

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

February 1, 2016

Completed
1.8 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 16, 2017

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

November 16, 2017

Completed
11 months until next milestone

First Submitted

Initial submission to the registry

September 27, 2018

Completed
15 days until next milestone

First Posted

Study publicly available on registry

October 12, 2018

Completed
2 months until next milestone

Results Posted

Study results publicly available

December 11, 2018

Completed
Last Updated

October 21, 2021

Status Verified

September 1, 2021

Enrollment Period

1.8 years

First QC Date

September 27, 2018

Results QC Date

November 16, 2018

Last Update Submit

September 27, 2021

Conditions

Keywords

Femoral Nerve BlockAdductor Canal Block

Outcome Measures

Primary Outcomes (3)

  • Quadriceps Muscle Activation as Assessed by Surface Electromyography (sEMG)

    Quadriceps muscle activation was examined using surface electromyography (sEMG) of the vastus medialis oblique muscle. Peak sEMG activity was recorded in microvolts (uV) on the surgical and contralateral limbs while performing five maximal effort isometric contractions in full knee extension--the reported values are equal to the quadriceps sEMG in uV of the contralateral limb minus the quadriceps sEMG in uV of the surgical limb.

    Post-operative day 1

  • Quadriceps Muscle Activation as Assessed by Surface Electromyography (EMG)

    Quadriceps muscle activation was examined using surface electromyography (sEMG) of the vastus medialis oblique muscle. Peak sEMG activity was recorded in microvolts (uV) on the surgical and contralateral limbs while performing five maximal effort isometric contractions in full knee extension--the reported values are equal to the quadriceps sEMG in uV of the contralateral limb minus the quadriceps sEMG in uV of the surgical limb.

    Post-operative day 14

  • Quadriceps Muscle Activation as Assessed by Surface Electromyography (EMG)

    Quadriceps muscle activation was examined using surface electromyography (sEMG) of the vastus medialis oblique muscle. Peak sEMG activity was recorded in microvolts (uV) on the surgical and contralateral limbs while performing five maximal effort isometric contractions in full knee extension--the reported values are equal to the quadriceps sEMG in uV of the contralateral limb minus the quadriceps sEMG in uV of the surgical limb.

    4 weeks post operative

Secondary Outcomes (17)

  • Number of Successful Repetitions With Straight Leg Raise Test

    Post-operative day 1

  • Number of Successful Repetitions With Straight Leg Raise Test

    Post-operative day 14

  • Number of Successful Repetitions With Straight Leg Raise Test

    4 weeks post operative

  • Postoperative Pain Control as Assessed by a Numeric Pain Rating Scale

    1 hr post surgery

  • Postoperative Pain Control as Assessed by a Numeric Pain Rating Scale

    2 hr post surgery

  • +12 more secondary outcomes

Study Arms (2)

Femoral Nerve Blockade

ACTIVE COMPARATOR

Ultrasound guided FNB (30 ml of 0.2% ropivacaine with 100 mcg clonidine using a 22-gauge 40 mm ProBloc II insulated needle; Kimberly-Clark, Roswell, Georgia) below the inguinal ligament using a high-frequency linear ultrasound transducer (4-12 Hz; Mindray M7; Mindray North America, Mahwah, NJ) with stimulator confirmation.

Drug: 30 ml of 0.2% ropivacaineDrug: 100 mcg clonidineDevice: High-frequency linear ultrasound transducer

Adductor Canal Blockade

ACTIVE COMPARATOR

Ultrasound guided ACB (15 ml of 0.2% ropivacaine with 100 mcg clonidine using a 22-gauge 40 mm ProBloc II insulated needle; Kimberly-Clark, Roswell, Georgia) at the mid-thigh using a high-frequency linear ultrasound transducer (4-12 Hz; Mindray M7; Mindray North America, Mahwah, NJ).

Drug: 15 ml of 0.2% ropivacaineDrug: 100 mcg clonidineDevice: High-frequency linear ultrasound transducer

Interventions

Femoral Nerve Blockade
Adductor Canal Blockade
Adductor Canal BlockadeFemoral Nerve Blockade
Adductor Canal BlockadeFemoral Nerve Blockade

Eligibility Criteria

Age16 Years - 30 Years
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64)

You may qualify if:

  • Males \& Females ages 16-30 yrs
  • Undergoing ACL reconstruction by Co-Investigator (Walter Lowe)
  • Receiving peri-operative FNB or ACB

You may not qualify if:

  • Not enrolled within the COFAKS study
  • Receiving intrathecal nerve blockade or no blockade

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

The University of Texas Health Science Center-Houston

Houston, Texas, 77030, United States

Location

Related Publications (5)

  • Duncan BR, Reid M, Kleihege J, Higbie S, Gardner EP, Lowe W, Bailey L. Comparison of Psychological Readiness to Return to Sport After Primary Versus Revision Anterior Cruciate Ligament Reconstruction. Orthop J Sports Med. 2023 May 2;11(5):23259671231159408. doi: 10.1177/23259671231159408. eCollection 2023 May.

  • Galloway C, Ward H, Higbie S, Kleihege J, Kumaravel M, Lowe WR, Bailey L. Relationship Between Bone Bruise Volume and Patient Outcomes After ACL Reconstruction. Orthop J Sports Med. 2023 Feb 24;11(2):23259671221146205. doi: 10.1177/23259671221146205. eCollection 2023 Feb.

  • Bailey L, Weldon M, Kleihege J, Lauck K, Syed M, Mascarenhas R, Lowe WR. Platelet-Rich Plasma Augmentation of Meniscal Repair in the Setting of Anterior Cruciate Ligament Reconstruction. Am J Sports Med. 2021 Oct;49(12):3287-3292. doi: 10.1177/03635465211036471. Epub 2021 Sep 3.

  • Worsham J, Lowe WR, Copa D, Williams S, Kleihege J, Lauck K, Mascarenhas R, Bailey L. Subsequent Surgery for Loss of Motion After Anterior Cruciate Ligament Reconstruction Does Not Influence Function at 2 Years: A Matched Case-Control Analysis. Am J Sports Med. 2019 Sep;47(11):2550-2556. doi: 10.1177/0363546519863347. Epub 2019 Jul 26.

  • Bailey L, Griffin J, Elliott M, Wu J, Papavasiliou T, Harner C, Lowe W. Adductor Canal Nerve Versus Femoral Nerve Blockade for Pain Control and Quadriceps Function Following Anterior Cruciate Ligament Reconstruction With Patellar Tendon Autograft: A Prospective Randomized Trial. Arthroscopy. 2019 Mar;35(3):921-929. doi: 10.1016/j.arthro.2018.10.149. Epub 2019 Feb 4.

MeSH Terms

Conditions

Anterior Cruciate Ligament Injuries

Interventions

RopivacaineClonidine

Condition Hierarchy (Ancestors)

Knee InjuriesLeg InjuriesWounds and Injuries

Intervention Hierarchy (Ancestors)

AnilidesAmidesOrganic ChemicalsAniline CompoundsAminesImidazolinesImidazolesAzolesHeterocyclic Compounds, 1-RingHeterocyclic Compounds

Results Point of Contact

Title
Lane Bailey, PhD, PT
Organization
The University of Texas Health Science Center at Houston

Study Officials

  • Lane Bailey, PhD, PT

    The University of Texas Health Science Center, Houston

    PRINCIPAL INVESTIGATOR

Publication Agreements

PI is Sponsor Employee
Yes

Study Design

Study Type
interventional
Phase
phase 4
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
PARTICIPANT
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Director of Research and Education

Study Record Dates

First Submitted

September 27, 2018

First Posted

October 12, 2018

Study Start

February 1, 2016

Primary Completion

November 16, 2017

Study Completion

November 16, 2017

Last Updated

October 21, 2021

Results First Posted

December 11, 2018

Record last verified: 2021-09

Data Sharing

IPD Sharing
Will not share

Locations